DK2220116T3 - Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza - Google Patents

Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza

Info

Publication number
DK2220116T3
DK2220116T3 DK08850112.7T DK08850112T DK2220116T3 DK 2220116 T3 DK2220116 T3 DK 2220116T3 DK 08850112 T DK08850112 T DK 08850112T DK 2220116 T3 DK2220116 T3 DK 2220116T3
Authority
DK
Denmark
Prior art keywords
diagnostication
influenza
therapy
procedures
compositions
Prior art date
Application number
DK08850112.7T
Other languages
English (en)
Inventor
Matthew Moyle
Andres G Grandea
Gordon King
Thomas Cox
Ole Olsen
Jennifer Mitcham
Original Assignee
Theraclone Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraclone Sciences Inc filed Critical Theraclone Sciences Inc
Application granted granted Critical
Publication of DK2220116T3 publication Critical patent/DK2220116T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK08850112.7T 2007-11-12 2008-11-12 Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza DK2220116T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98735507P 2007-11-12 2007-11-12
US98735307P 2007-11-12 2007-11-12
US5384008P 2008-05-16 2008-05-16
US9520808P 2008-09-08 2008-09-08
PCT/US2008/083265 WO2009064805A1 (en) 2007-11-12 2008-11-12 Compositions and methods for the therapy and diagnosis of influenza

Publications (1)

Publication Number Publication Date
DK2220116T3 true DK2220116T3 (da) 2012-11-26

Family

ID=40404221

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08850112.7T DK2220116T3 (da) 2007-11-12 2008-11-12 Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza

Country Status (15)

Country Link
US (4) US8057796B2 (da)
EP (1) EP2220116B1 (da)
JP (2) JP4932940B2 (da)
KR (1) KR20100097691A (da)
CN (2) CN104059143A (da)
AU (1) AU2008321016B2 (da)
CA (1) CA2705555A1 (da)
DK (1) DK2220116T3 (da)
ES (1) ES2395784T3 (da)
HK (1) HK1202558A1 (da)
IL (1) IL205705A (da)
MX (1) MX2010005244A (da)
NZ (1) NZ585500A (da)
PT (1) PT2220116E (da)
WO (1) WO2009064805A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
CN104059143A (zh) 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
US8329188B2 (en) * 2008-11-12 2012-12-11 Theraclone Sciences, Inc. Human M2e peptide immunogens
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2011019932A2 (en) * 2009-08-14 2011-02-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US8900590B2 (en) * 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
CN102172348B (zh) * 2011-02-12 2013-02-20 北京博康宁生物医药科技有限公司 固体的磷酸奥司他韦药物组合物
CA2827301A1 (en) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
DK2683736T3 (da) * 2011-03-09 2018-04-23 Cell Signaling Technology Inc Fremgangsmåder og reagenser til at skabe monoklonale antistoffer
US20120315277A1 (en) * 2011-03-15 2012-12-13 Theraclone Sciences, Inc. Compositions and Methods for the Therapy and Diagnosis of Influenza
ES2822199T3 (es) * 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel
MX346625B (es) 2011-06-24 2017-03-27 Flugen Inc Mutantes de virus de influenza y usos para los mismos.
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
PE20151604A1 (es) 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
JP2016519688A (ja) * 2013-04-22 2016-07-07 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
JP6262969B2 (ja) 2013-09-10 2018-01-17 デンカ生研株式会社 Ａ型インフルエンザウイルスの測定方法
JP6182027B2 (ja) 2013-09-10 2017-08-16 デンカ生研株式会社 Ｂ型インフルエンザウイルスの測定方法
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
JP6545981B2 (ja) 2015-03-12 2019-07-17 アルパッド株式会社 半導体発光装置
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SI3589730T1 (sl) 2017-02-28 2024-04-30 The Trustees Of The University Of Pennsylvania Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
US10786568B2 (en) 2017-02-28 2020-09-29 The Trustees Of The University Of Pennsylvania AAV mediated influenza vaccines
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
WO1996016673A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US20050170334A1 (en) 2002-03-13 2005-08-04 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
KR20040111402A (ko) 2002-03-13 2004-12-31 기린 비루 가부시키가이샤 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
CN1738831A (zh) * 2002-11-13 2006-02-22 拉特格斯州立大学 流感病毒非结构蛋白1抑制剂的设计方法
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
US8124091B2 (en) * 2004-12-06 2012-02-28 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
AU2006290736B2 (en) * 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
CA2690973A1 (en) * 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
CN101015691B (zh) * 2006-11-14 2010-08-25 中国医学科学院医学生物学研究所 重组噬菌体流感疫苗
CN104059143A (zh) * 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
WO2010063675A1 (en) 2008-12-04 2010-06-10 Cytos Biotechnology Ag Fully human influenza m2 specific antibodies
WO2011019932A2 (en) * 2009-08-14 2011-02-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA2827301A1 (en) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
JP2016519688A (ja) * 2013-04-22 2016-07-07 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法

Also Published As

Publication number Publication date
CN102089324A (zh) 2011-06-08
US20120171218A1 (en) 2012-07-05
PT2220116E (pt) 2012-12-07
HK1147767A1 (en) 2011-08-19
JP2011178804A (ja) 2011-09-15
JP4932940B2 (ja) 2012-05-16
AU2008321016B2 (en) 2013-03-28
US20100178295A1 (en) 2010-07-15
MX2010005244A (es) 2010-10-25
AU2008321016A1 (en) 2009-05-22
JP2011501737A (ja) 2011-01-13
US20140135480A1 (en) 2014-05-15
US8114402B2 (en) 2012-02-14
IL205705A (en) 2016-06-30
HK1202558A1 (en) 2015-10-02
US8460671B2 (en) 2013-06-11
KR20100097691A (ko) 2010-09-03
US8057796B2 (en) 2011-11-15
EP2220116B1 (en) 2012-09-05
IL205705A0 (en) 2010-11-30
US20090226433A1 (en) 2009-09-10
EP2220116A1 (en) 2010-08-25
CA2705555A1 (en) 2009-05-22
ES2395784T3 (es) 2013-02-15
NZ585500A (en) 2012-06-29
JP5623332B2 (ja) 2014-11-12
WO2009064805A1 (en) 2009-05-22
CN102089324B (zh) 2014-04-16
CN104059143A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2048941T3 (da) Fremgangsmåde til opdræt af rovmider
DK2231565T3 (da) Fremgangsmåder til fremstilling af clorerede carbonhydrider
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK2229360T3 (da) Indolinonderivater og fremgangsmåde til deres fremstilling
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2124571T3 (da) Fremgangsmåde til fremstilling og påføring af en sprøjtbar pesticid- eller herbicidformulering
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære